Serum cholesterol and nigrostriatal R2* values in Parkinson's disease

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Du, Guangwei ^a   Lewis, Mechelle M ^a   Shaffer, Michele L ^a   Chen, Honglei ^b   Yang, Qing X ^a   Mailman, Richard B ^a   Huang, Xuemei ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CAUDATE NUCLEUS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOBUS PALLIDUS; HUMAN; IRON STORAGE; MALE; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PROTON TRANSVERSE RELAXATION RATE; PUTAMEN; RADIOLOGICAL PARAMETERS; SUBSTANTIA NIGRA;

AGED; CHOLESTEROL; FEMALE; GLOBUS PALLIDUS; HUMANS; IRON; LIPOPROTEINS, LDL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84859810065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035397     Document Type: Article

References (57)

1. Fearnley JM, Lees AJ, (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5): 2283-2301.
2. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, et al. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836.
3. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, et al. (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199-205.
4. Griffiths PD, Dobson BR, Jones GR, Clarke DT, (1999) Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122 (Pt 4): 667-673.
5. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, et al. (2005) Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 23: 1-25.
6. Martin WR, Wieler M, Gee M, (2008) Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70: 1411-1417.
7. Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, et al. (2010) Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 257: 455-462.
8. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, et al. (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45: 1138-1143.
9. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD, (2000) Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123 Pt 12: 2423-2431.
10. Baudrexel S, Nurnberger L, Rub U, Seifried C, Klein JC, et al. (2010) Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage.
11. Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, et al. (2010) Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain.
12. Du G, Lewis MM, Styner M, Shaffer ML, Sen S, et al. (2011) Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease. Mov Disord.
13. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR, (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873.
14. Benarroch EE, (2009) Brain iron homeostasis and neurodegenerative disease. Neurology 72: 1436-1440.
15. Gregory A, Hayflick SJ, (2005) Neurodegeneration with brain iron accumulation. Folia Neuropathol 43: 286-296.
16. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, et al. (2001) A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28: 345-349.
17. Gitlin JD, (1998) Aceruloplasminemia. Pediatr Res 44: 271-276.
18. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, et al. (2001) Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 28: 350-354.
19. Lavaute T, Smith S, Cooperman S, Iwai K, Land W, et al. (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 27: 209-214.
20. Jenner P, (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3): S26-S36.
21. Altamura S, Muckenthaler MU, (2009) Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 16: 879-895.
22. Tofaris GK, Revesz T, Jacques TS, Papacostas S, Chataway J, (2007) Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity. Arch Neurol 64: 280-282.
23. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, et al. (1995) Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 65: 710-724.
24. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, et al. (2008) Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 106: 1866-1875.
25. Beard J, (2003) Iron deficiency alters brain development and functioning. J Nutr 133: 1468S-1472S.
26. Beard JL, Connor JR, Jones BC, (1993) Iron in the brain. Nutr Rev 51: 157-170.
27. Huang X, Chen H, Miller WC, Mailman R, Woodard JL, et al. (2007) Lower LDL cholesterol levels are associated with Parkinson's disease: a case control study. Mov Disord 22: 377-381.
28. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, et al. (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37: 1184-1188.
29. Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, et al. (2010) Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 293: 82-86.
30. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW, (2008) Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 23: 1013-1018.
31. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM, (2006) Serum Cholesterol Levels and the Risk of Parkinson's Disease. Am J Epidemiol 164: 998-1002.
32. Simon KC, Chen H, Schwarzschild M, Ascherio A, (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69: 1688-1695.
33. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, et al. (2011) Serum Cholesterol and the Progression of Parkinson's Disease: Results from DATATOP. PloS ONE In Press.
34. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J, (2008) Total cholesterol and the risk of Parkinson disease. Neurology 70: 1972-1979.
35. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, et al. (2009) Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat Disord 15: 47-52.
36. Calne DB, Snow BJ, Lee C, (1992) Criteria for diagnosing Parkinson's disease. Ann Neurol 32 (Suppl): S125-S127.
37. Herzog J, Volkmann J, Krack P, Kopper F, Potter M, et al. (2003) Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 18: 1332-1337.
38. Denk C, Rauscher A, (2010) Susceptibility weighted imaging with multiple echoes. J Magn Reson Imaging 31: 185-191.
39. Vaillancourt DE, Spraker MB, Prodoehl J, Zhou XJ, Little DM, (2010) Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging. Neurobiol Aging.
40. Massey LA, Yousry TA, (2010) Anatomy of the substantia nigra and subthalamic nucleus on MR imaging. Neuroimaging Clin N Am 20: 7-27.
41. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, et al. (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31: 1116-1128.
42. Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K, (2002) The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. AJNR Am J Neuroradiol 23: 1747-1756.
43. Manova ES, Habib CA, Boikov AS, Ayaz M, Khan A, et al. (2009) Characterizing the mesencephalon using susceptibility-weighted imaging. AJNR Am J Neuroradiol 30: 569-574.
44. Kwon DH, Kim JM, Oh SH, Jeong HJ, Park SY, et al. (2012) Seven-tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 71: 267-277.
45. Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schafer A, et al. (2012) High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 35: 48-55.
46. Damier P, Hirsch EC, Agid Y, Graybiel AM, (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (Pt 8): 1437-1448.
47. Damier P, Hirsch EC, Agid Y, Graybiel AM, (1999) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 122 (Pt 8): 1421-1436.
48. Joshi S, Davis B, Jomier M, Gerig G, (2004) Unbiased diffeomorphic atlas construction for computational anatomy. Neuroimage 23 (Suppl 1): S151-S160.
49. Gouttard S, Styner M, Joshi S, Smith RG, Hazlett HC, et al. (2007) Subcortical structure segmentation using probabilistic atlas priors. Medical Image Computing and Computer Assisted Intervention Workshop pp. 37-46.
50. Ikeda K, Nakamura Y, Kiyozuka T, Aoyagi J, Hirayama T, et al. (2011) Serological Profiles of Urate, Paraoxonase-1, Ferritin and Lipid in Parkinson's Disease: Changes Linked to Disease Progression. Neurodegener Dis.
51. Hallgren B, Sourander P, (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3: 41-51.
52. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, et al. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (Pt 4): 1953-1975.
53. Dorman DC, Struve MF, Wong BA, Dye JA, Robertson ID, (2006) Correlation of brain magnetic resonance imaging changes with pallidal manganese concentrations in rhesus monkeys following subchronic manganese inhalation. Toxicol Sci 92: 219-227.
54. Klos KJ, Chandler M, Kumar N, Ahlskog JE, Josephs KA, (2006) Neuropsychological profiles of manganese neurotoxicity. Eur J Neurol 13: 1139-1141.
55. Griffiths PD, Crossman AR, (1996) Autoradiography of transferrin receptors in the human brain. Neurosci Lett 211: 53-56.
56. Stepien K, Tomaszewski M, Czuczwar SJ, (2005) Neuroprotective properties of statins. Pharmacol Rep 57: 561-569.
57. Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, et al. (2008) Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem 105: 1656-1667.